

Changes in Prolia[®] coverage

Security Health Plan is replacing the biologic Prolia[®] (denosumab), which is primarily used to treat osteoporosis and bone loss, in its formulary with the preferred biosimilars Stoboclo (denosumab-bmwo) and Jubbonti (denosumab-bbdz) effective April 1, 2026.

Both Stoboclo and Jubbonti are FDA-approved with no clinically meaningful differences in safety, effectiveness, dosing or indications, which means no changes are needed in clinical decision-making, dosing or monitoring.

Providers who have patients with circumstances requiring them to stay on Prolia[®] can submit a prior authorization request.

If you have any questions about Security Health Plan's pharmacy benefits, please contact Security Health Plan pharmacy services at (877) 873-5611, (715) 221-9604 or shprx@securityhealth.org.